Key result
SGLT2 inhibitor initiation linked to a ~5-mmHg drop in systolic BP in treated hypertension.
Why the study?
SGLT2 inhibitors demonstrate blood pressure reduction benefits, prompting evaluation of blood pressure changes and antihypertensive medication use before and after initiation.
Does initiation of SGLT2 inhibitors reduce blood pressure and antihypertensive medication burden in patients with treated hypertension, including those with apparent treatment-resistant hypertension or proteinuria?
Cohort (n=12,960)
Yes
Does initiation of SGLT2 inhibitors reduce blood pressure and antihypertensive medication burden in patients with treated hypertension, including those with apparent treatment-resistant hypertension or proteinuria?
In a large real-world cohort of patients with treated hypertension, initiating an SGLT2 inhibitor was associated with clinically meaningful reductions in blood pressure and allowed one-third of patients to discontinue at least one antihypertensive medication.
Answers are grounded in this paper and cite their sources.
Supports BP lowering and deprescribing with SGLT2 inhibitors in treated hypertension; leaves open randomized confirmation before practice change.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated a blood pressure (BP) reduction benefit despite other indications for use. We evaluated BP changes and antihypertensive medication use pre- and post-SGLT2i initiation among 12 960 patients with treated hypertension and among subgroups with apparent treatment-resistant hypertension (aTRH) and/or proteinuria. Post-SGLT2i initiation, the mean (SD) systolic blood pressure (SBP) was reduced from 133.9 (16.4) to 128.6 (15.5) mmHg and the mean diastolic blood pressure (DBP) was reduced from 70.8 (11.8) to 68.3 (11.3) mmHg among all patients. The mean SBP/DBP reduction was 5.3/2.5, 6.2/2.8, and 6.1/2.9 mmHg among all patients, patients with aTRH, and patients with proteinuria, respectively. Achieved BP < 130/80 mmHg increased by 12.5%, 16.9%, and 11.1% for all patients, patients with aTRH, and patients with proteinuria, respectively. Discontinuation of ≥ 1 antihypertensive medication within 12 months of SGLT2i initiation occurred in 33.4% overall, 47.6% of patients with aTRH, and 38.7% of patients with proteinuria.
No takes yet. Share an insight, caveat, or question.
An et al. (2024) conducted a cohort in Treated hypertension (n=12,960). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. Pre-SGLT2i initiation baseline was evaluated on Outpatient systolic blood pressure (SBP) change from before to after SGLT2i initiation (MD -5.3 mmHg). SGLT2 inhibitor initiation reduced mean systolic/diastolic blood pressure by 5.3/2.5 mmHg and led to antihypertensive medication discontinuation in 33.4% of patients with treated hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: